AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. PHIO
  4. [Form 3] Phio Pharmaceuticals Corp. Initial Statement of Beneficial Ownership

[Form 3] Phio Pharmaceuticals Corp. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3
Rhea-AI Filing Summary

Form 3 Initial Statement of Beneficial Ownership filed by Lisa Cabott Carson for Phio Pharmaceuticals (NASDAQ: PHIO) on June 28, 2025, reporting her beneficial ownership position as of June 6, 2025.

Key details:

  • Carson has been appointed as VP, Finance and Administration at Phio Pharmaceuticals
  • Currently holds no beneficial ownership of any securities, either direct or indirect
  • Filing includes no derivative securities ownership (options, warrants, etc.)
  • Individual filing submitted with Power of Attorney documentation (Exhibit 24)

This Form 3 establishes the baseline ownership position for the new officer's future transaction reporting requirements under SEC Section 16(a).

Dichiarazione Iniziale di Propriet脿 Beneficiaria - Modulo 3 presentata da Lisa Cabott Carson per Phio Pharmaceuticals (NASDAQ: PHIO) il 28 giugno 2025, che riporta la sua posizione di propriet脿 beneficiaria al 6 giugno 2025.

Dettagli principali:

  • Carson 猫 stata nominata Vicepresidente, Finanza e Amministrazione presso Phio Pharmaceuticals
  • Attualmente non detiene alcuna propriet脿 beneficiaria di titoli, n茅 diretta n茅 indiretta
  • La dichiarazione non include la propriet脿 di titoli derivati (opzioni, warrant, ecc.)
  • Dichiarazione individuale presentata con documentazione di procura (Allegato 24)

Questo Modulo 3 stabilisce la posizione di propriet脿 di riferimento per i futuri obblighi di segnalazione delle transazioni del nuovo dirigente secondo la Sezione 16(a) della SEC.

Formulario 3 Declaraci贸n Inicial de Propiedad Beneficiaria presentado por Lisa Cabott Carson para Phio Pharmaceuticals (NASDAQ: PHIO) el 28 de junio de 2025, reportando su posici贸n de propiedad beneficiaria al 6 de junio de 2025.

Detalles clave:

  • Carson ha sido nombrada Vicepresidenta de Finanzas y Administraci贸n en Phio Pharmaceuticals
  • Actualmente no posee ninguna propiedad beneficiaria de valores, ni directa ni indirectamente
  • La presentaci贸n no incluye propiedad de valores derivados (opciones, warrants, etc.)
  • Presentaci贸n individual acompa帽ada de documentaci贸n de poder notarial (Anexo 24)

Este Formulario 3 establece la posici贸n base de propiedad para los futuros requisitos de reporte de transacciones del nuevo ejecutivo bajo la Secci贸n 16(a) de la SEC.

靻岇湢甓� 齑堦赴 鞁犼碃靹�(Form 3)臧� 2025雲� 6鞗� 28鞚� Lisa Cabott Carson鞐� 鞚橅暣 Phio Pharmaceuticals (NASDAQ: PHIO)毳� 鞙勴暣 鞝滌稖霅橃棃鞙茧┌, 2025雲� 6鞗� 6鞚� 旮办 攴鸽厐鞚� 鞁れ 靻岇湢 歆�鞙勲ゼ 氤搓碃頃╇媹雼�.

欤检殧 雮挫毄:

  • Carson鞚� Phio Pharmaceuticals鞚� 鞛 氚� 甏�毽� 攵�靷灔鞙茧 鞛勲獏霅橃棃鞀惦媹雼�
  • 順勳灛 歆侅爲 霕愲姅 臧勳爲鞝侅溂搿� 鞏措枲頃� 歃濌秾鞚� 鞁れ 靻岇湢甓岆弰 氤挫湢頃橁碃 鞛堨 鞎婌姷雼堧嫟
  • 韺岇儩 歃濌秾(鞓奠厴, 鞗岆煱韸� 霌�) 靻岇湢甓岇潃 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟
  • 鞙勳瀯鞛� 靹滊(觳秬氍胳劀 24)鞕� 頃粯 鞝滌稖霅� 臧滌澑 鞁犼碃靹滌瀰雼堧嫟

鞚� Form 3電� SEC 靹轨厴 16(a)鞐� 霐半ジ 鞁犼窚 鞛勳洂鞚� 頄ロ泟 瓯半灅 鞁犼碃 鞚橂毳� 鞙勴暅 旮办 靻岇湢甓� 鞙勳箻毳� 靹れ爼頃╇媹雼�.

D茅claration Initiale de D茅tention B茅n茅ficiaire - Formulaire 3 d茅pos茅e par Lisa Cabott Carson pour Phio Pharmaceuticals (NASDAQ : PHIO) le 28 juin 2025, rapportant sa position de d茅tention b茅n茅ficiaire au 6 juin 2025.

D茅tails cl茅s :

  • Carson a 茅t茅 nomm茅e Vice-Pr茅sidente, Finance et Administration chez Phio Pharmaceuticals
  • Ne d茅tient actuellement aucune propri茅t茅 b茅n茅ficiaire de titres, ni directe ni indirecte
  • Le d茅p么t n'inclut aucune d茅tention de titres d茅riv茅s (options, bons de souscription, etc.)
  • D茅p么t individuel soumis avec documentation de procuration (Annexe 24)

Ce Formulaire 3 茅tablit la position initiale de d茅tention pour les futures obligations de d茅claration des transactions du nouveau dirigeant selon la Section 16(a) de la SEC.

Formular 3 - Erste Erkl盲rung zum wirtschaftlichen Eigentum eingereicht von Lisa Cabott Carson f眉r Phio Pharmaceuticals (NASDAQ: PHIO) am 28. Juni 2025, mit Angabe ihres wirtschaftlichen Eigentums zum 6. Juni 2025.

Wichtige Details:

  • Carson wurde zur VP f眉r Finanzen und Verwaltung bei Phio Pharmaceuticals ernannt
  • H盲lt derzeit keine wirtschaftlichen Eigentumsrechte an Wertpapieren, weder direkt noch indirekt
  • Die Einreichung beinhaltet keinen Besitz von Derivaten (Optionen, Warrants usw.)
  • Einzelmeldung mit Vollmachtsdokumentation (Anlage 24) eingereicht

Dieses Formular 3 legt die Ausgangsbasis f眉r die zuk眉nftigen Meldepflichten des neuen Leiters gem盲脽 SEC Abschnitt 16(a) fest.

Positive
  • None.
Negative
  • None.

Dichiarazione Iniziale di Propriet脿 Beneficiaria - Modulo 3 presentata da Lisa Cabott Carson per Phio Pharmaceuticals (NASDAQ: PHIO) il 28 giugno 2025, che riporta la sua posizione di propriet脿 beneficiaria al 6 giugno 2025.

Dettagli principali:

  • Carson 猫 stata nominata Vicepresidente, Finanza e Amministrazione presso Phio Pharmaceuticals
  • Attualmente non detiene alcuna propriet脿 beneficiaria di titoli, n茅 diretta n茅 indiretta
  • La dichiarazione non include la propriet脿 di titoli derivati (opzioni, warrant, ecc.)
  • Dichiarazione individuale presentata con documentazione di procura (Allegato 24)

Questo Modulo 3 stabilisce la posizione di propriet脿 di riferimento per i futuri obblighi di segnalazione delle transazioni del nuovo dirigente secondo la Sezione 16(a) della SEC.

Formulario 3 Declaraci贸n Inicial de Propiedad Beneficiaria presentado por Lisa Cabott Carson para Phio Pharmaceuticals (NASDAQ: PHIO) el 28 de junio de 2025, reportando su posici贸n de propiedad beneficiaria al 6 de junio de 2025.

Detalles clave:

  • Carson ha sido nombrada Vicepresidenta de Finanzas y Administraci贸n en Phio Pharmaceuticals
  • Actualmente no posee ninguna propiedad beneficiaria de valores, ni directa ni indirectamente
  • La presentaci贸n no incluye propiedad de valores derivados (opciones, warrants, etc.)
  • Presentaci贸n individual acompa帽ada de documentaci贸n de poder notarial (Anexo 24)

Este Formulario 3 establece la posici贸n base de propiedad para los futuros requisitos de reporte de transacciones del nuevo ejecutivo bajo la Secci贸n 16(a) de la SEC.

靻岇湢甓� 齑堦赴 鞁犼碃靹�(Form 3)臧� 2025雲� 6鞗� 28鞚� Lisa Cabott Carson鞐� 鞚橅暣 Phio Pharmaceuticals (NASDAQ: PHIO)毳� 鞙勴暣 鞝滌稖霅橃棃鞙茧┌, 2025雲� 6鞗� 6鞚� 旮办 攴鸽厐鞚� 鞁れ 靻岇湢 歆�鞙勲ゼ 氤搓碃頃╇媹雼�.

欤检殧 雮挫毄:

  • Carson鞚� Phio Pharmaceuticals鞚� 鞛 氚� 甏�毽� 攵�靷灔鞙茧 鞛勲獏霅橃棃鞀惦媹雼�
  • 順勳灛 歆侅爲 霕愲姅 臧勳爲鞝侅溂搿� 鞏措枲頃� 歃濌秾鞚� 鞁れ 靻岇湢甓岆弰 氤挫湢頃橁碃 鞛堨 鞎婌姷雼堧嫟
  • 韺岇儩 歃濌秾(鞓奠厴, 鞗岆煱韸� 霌�) 靻岇湢甓岇潃 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟
  • 鞙勳瀯鞛� 靹滊(觳秬氍胳劀 24)鞕� 頃粯 鞝滌稖霅� 臧滌澑 鞁犼碃靹滌瀰雼堧嫟

鞚� Form 3電� SEC 靹轨厴 16(a)鞐� 霐半ジ 鞁犼窚 鞛勳洂鞚� 頄ロ泟 瓯半灅 鞁犼碃 鞚橂毳� 鞙勴暅 旮办 靻岇湢甓� 鞙勳箻毳� 靹れ爼頃╇媹雼�.

D茅claration Initiale de D茅tention B茅n茅ficiaire - Formulaire 3 d茅pos茅e par Lisa Cabott Carson pour Phio Pharmaceuticals (NASDAQ : PHIO) le 28 juin 2025, rapportant sa position de d茅tention b茅n茅ficiaire au 6 juin 2025.

D茅tails cl茅s :

  • Carson a 茅t茅 nomm茅e Vice-Pr茅sidente, Finance et Administration chez Phio Pharmaceuticals
  • Ne d茅tient actuellement aucune propri茅t茅 b茅n茅ficiaire de titres, ni directe ni indirecte
  • Le d茅p么t n'inclut aucune d茅tention de titres d茅riv茅s (options, bons de souscription, etc.)
  • D茅p么t individuel soumis avec documentation de procuration (Annexe 24)

Ce Formulaire 3 茅tablit la position initiale de d茅tention pour les futures obligations de d茅claration des transactions du nouveau dirigeant selon la Section 16(a) de la SEC.

Formular 3 - Erste Erkl盲rung zum wirtschaftlichen Eigentum eingereicht von Lisa Cabott Carson f眉r Phio Pharmaceuticals (NASDAQ: PHIO) am 28. Juni 2025, mit Angabe ihres wirtschaftlichen Eigentums zum 6. Juni 2025.

Wichtige Details:

  • Carson wurde zur VP f眉r Finanzen und Verwaltung bei Phio Pharmaceuticals ernannt
  • H盲lt derzeit keine wirtschaftlichen Eigentumsrechte an Wertpapieren, weder direkt noch indirekt
  • Die Einreichung beinhaltet keinen Besitz von Derivaten (Optionen, Warrants usw.)
  • Einzelmeldung mit Vollmachtsdokumentation (Anlage 24) eingereicht

Dieses Formular 3 legt die Ausgangsbasis f眉r die zuk眉nftigen Meldepflichten des neuen Leiters gem盲脽 SEC Abschnitt 16(a) fest.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Carson Lisa Cabott
(Last) (First) (Middle)
C/O PHIO PHARMACEUTICALS CORP.
11 APEX DR., SUITE 300A, PMB 2006
(Street)
MARLBOROUGH MA 01752
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/06/2025 		3. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, Finance and Administration
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
No securities are beneficially owned.
/s/ Lisa C. Carson 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who is the new VP of Finance and Administration at PHIO Pharmaceuticals (PHIO)?

Lisa Cabott Carson was appointed as VP of Finance and Administration at PHIO Pharmaceuticals, as disclosed in a Form 3 filing dated June 28, 2025.

When did Lisa Carson join PHIO Pharmaceuticals (PHIO) as an officer?

According to the Form 3 filing, the date of event requiring statement was June 6, 2025, which indicates when Lisa Carson became an officer (VP of Finance and Administration) at PHIO Pharmaceuticals.

Does Lisa Carson own any shares of PHIO Pharmaceuticals stock?

No, according to the Form 3 filing, Lisa Carson does not beneficially own any securities of PHIO Pharmaceuticals. This is explicitly stated in the 'Remarks' section: 'No securities are beneficially owned.'

What position does Lisa Carson hold at PHIO Pharmaceuticals (PHIO)?

Lisa Carson holds the position of Vice President of Finance and Administration at PHIO Pharmaceuticals, as disclosed in the Form 3 filing under Section 4 'Relationship of Reporting Person(s) to Issuer.'

Where is PHIO's new VP of Finance and Administration based?

According to the Form 3 filing, Lisa Carson's business address is at PHIO Pharmaceuticals Corp.'s headquarters at 11 Apex Dr., Suite 300A, PMB 2006, Marlborough, MA 01752.
Stock PHIO logo
Phio Pharmaceuticals Corp

NASDAQ:PHIO

PHIO Rankings

#10104 Ranked by Market Cap
N/A Ranked by Dividends

PHIO Latest News

Jul 25, 2025
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Jul 25, 2025
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
Jul 25, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
Jun 25, 2025
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Jun 24, 2025
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

PHIO Latest SEC Filings

Jul 25, 2025
[8-K] Phio Pharmaceuticals Corp. Reports Material Event
Jul 7, 2025
[8-K] Phio Pharmaceuticals Corp. Reports Material Event

PHIO Stock Data

12.19M
4.77M
0.29%
16.96%
1.4%
Biotechnology
Pharmaceutical Preparations
United States
MARLBOROUGH